It would be interesting to know if this happened after first dose or second doseNorwegian officials have adjusted their advice on who gets the COVID-19 vaccine in light of a small number of deaths in older people, leaving it up to each doctor to consider who should be vaccinated.
This is the total for entire population right! If we just look at the numbers for elderly, the vaccination totals may be far less
But I think those deaths came from Pfizer and Moderna vaccines, not AstraZeneca(Oxford). It is all pretty confusing. I think the whole world is taking some chances and letting things get started. There will be a bit of an unsettled few months before everything becomes somewhat clear.Kumar wrote: ↑Sat Jan 16, 2021 7:00 pmThis is the total for entire population right! If we just look at the numbers for elderly, the vaccination totals may be far less. Very troublesome! And I don’t think Oxford did whole lot of testing with elderly! May definitely scare off elderly people and their caregivers
True. I have started keeping a spreadsheet (assuming the data will be available daily like tweeted out by the ministry today) to calculate basic stats. Among the larger states, AP leads after one day with 353 shots per million population. Kerala, Delhi and Karnataka follow with 230, 218 and 207. At the bottom end, TN is the worst at 39, with Punjab, Jharkhand, UP, TEL, WB with 44, 83, 95, 98 and 100... The national average is 143.
Abstract: Background: India has been amongst the most affected nations during the SARS CoV2 pandemic, with sparse data on country wide spread of asymptomatic infections and antibody persistence. This longitudinal cohort study was aimed to evaluate SARS CoV2 seropositivity rate as a marker of infection and evaluate temporal persistence of antibodies with neutralization capability and to infer possible risk factors for infection. Methods: Council of Scientific and Industrial Research, India (CSIR) with its more than 40 laboratories and centers in urban and semi urban settings spread across the country piloted the pan country surveillance. 10427 adult individuals working in CSIR laboratories and their family members based on voluntary participation were assessed for antibody presence and stability was analyzed over 6 months utilizing qualitative Elecysys SARS CoV2 specific antibody kit and GENScript cPass SARS CoV2 Neutralization Antibody Detection Kit. Along with demographic information, possible risk factors were evaluated through self to be filled online forms with data acquired on blood group type, occupation type, addiction and habits including smoking and alcohol, diet preferences, medical history and transport type utilized. Symptom history and information on possible contact and compliance with COVID 19 universal precautions was also obtained. Findings:1058 individuals (10.14%) had antibodies against SARS CoV2. A follow up on 346 seropositive individuals after three months revealed stable to higher antibody levels against SARS CoV2 but declining plasma activity for neutralizing SARS CoV2 receptor binding domain and ACE2 interaction. A repeat sampling of 35 individuals, at six months, revealed declining antibody levels while the neutralizing activity remained stable compared to three months. Majority of seropositive individuals (75%) did not recall even one of nine symptoms since March 2020. Fever was the most common symptom with one fourth reporting loss of taste or smell. Significantly associated risks for seropositivity (Odds Ratio, 95% CI, p value) were observed with usage of public transport (1.79, 1.43 to 2∙24, 2.81561x10-6), occupational responsibilities such as security, housekeeping personnel etc. (2.23, 1.92 to 2.59, 6.43969x10-26), non smokers (1.52, 1.16 to 1.99, 0.02) and non vegetarianism (1.67, 1.41 to 1.99, 3.03821x10-8). An iterative regression analysis was confirmatory and led to only modest changes to estimates. Predilections for seropositivity was noted with specific ABO blood groups; O was associated with a lower risk. Interpretation: In a first of its kind study from India, we report the seropositivity in a country wide cohort and identify variable susceptible associations for contacting infection. Serology and Neutralizing Antibody response provides much sought for general insights on the immune response to the virus among Indians and will be an important resource for designing vaccination strategies. Funding: Council of Scientific and Industrial Research, India (CSIR)
This was quite an interesting study. I took a quick look at the paper too. Here is a summary from Indian Express - Seropositivity for COVID-19 found to be lesser in smokers, vegetarians: CSIR surveysuresh wrote: ↑Sun Jan 17, 2021 12:46 pm FYI
Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2